On a per-share basis, the St. Louis-based company said it had a loss of 56 cents. When adjusted for one-time gains and costs, the company turned a profit of 11 cents per share. The results beat Wall Street expectations for a loss of 24 cents per share, according to the average estimate of nine analysts surveyed by Zacks Investment Research.
The agriculture products company posted lower revenue of USD 2.22 billion in the period, falling short of Street forecasts. Three analysts surveyed by Zacks expected USD 2.55 billion.
Monsanto's biotech seeds have genetically engineered traits that help farmers increase their crop yield, despite their higher prices. Monsanto has dominated the bioengineered-seed business for more than a decade and recently began developing products specifically for emerging markets like Argentina, Brazil and parts of Asia.
Monsanto shares fell USD 2.28, or 2.3 percent, to USD 95 in premarket trading about 45 minutes before the market open. Its shares have fallen slightly more than 1 percent since the beginning of the year, while the Standard & Poor's 500 index has dropped slightly more than 1 percent. The stock has dropped 17 percent in the last 12 months.